Sept 5 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO
* Ortho dermatologics submits new drug application to the u.s. Food and drug administration for psoriasis treatment idp-118
* Valeant - in both studies IDP-118 met primary efficacy endpoint
* Valeant - ortho dermatologics' nda for idp-118 also includes long-term safety study with patients followed for one year